Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Controlled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive and Mucosal Infections.

Trial Profile

Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Controlled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive and Mucosal Infections.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2013

At a glance

  • Drugs Haemophilus influenzae-pneumococcal vaccine (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Otitis media; Pneumococcal infections; Respiratory tract infections
  • Focus Therapeutic Use
  • Acronyms PREV-IX_BOOST
  • Most Recent Events

    • 14 Jan 2013 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 05 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top